Skip to main content

Advertisement

SpringerLink
Log in

New Antipsychotic Medications in the Last Decade

  • Schizophrenia and Other Psychotic Disorders (AK Pandurangi, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Over the last ten years, the treatment of psychosis has seen a near explosion of creative development in both novel agents and new delivery modalities. The current review summarizes these developments over the past decade (2011–2020). We performed a systematic review utilizing PubMed and PsychInfo with the aim of identifying all the RCT and related analyses in adults with psychosis (schizophrenia and mania).

Recent Findings

We identified 11 significant developments: the introduction of new antipsychotics cariprazine, brexpiprazole, lumateperone, and pimavanserin; introduction of new delivery methods: subcutaneous long-acting risperidone, aripiprazole lauroxil, transdermal asenapine, and inhaled loxapine; and the introduction of new approaches such as olanzapine/samidorphan for olanzapine-associated weight gain, examination of the TAAR1 agonist SEP 363,856 as a test of concept, and the combination of Xanomeline/Trospium, an M1 and M4 muscarinic receptor agonist in conjunction with a peripheral anticholinergic.

Summary

Last decade has seen a tremendous development in second-generation antipsychotics which provides unprecedented treatment options for clinicians in treating psychosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Kalin NH. Developing innovative and novel treatment strategies. Am J Psychiatry. 2019;176(11):885–7.

  2. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

  3. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

  4. McCormack PL. Cariprazine: first global approval. Drugs. 2015;75(17):2035–43.

    Article  CAS  PubMed  Google Scholar 

  5. Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horvath A, Pasztor G, et al. Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. 2011;218(3):579–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Toth M, Varrone A, Steiger C, Laszlovszky I, Horvath A, Kiss B, et al. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C] cariprazine: an in vivo positron emission tomography study in nonhuman primates. Synapse. 2013;67(5):258–64.

    Article  CAS  PubMed  Google Scholar 

  7. Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123–7.

    Article  PubMed  Google Scholar 

  8. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–40.

    Article  CAS  PubMed  Google Scholar 

  9. Agai-Csongor E, Domany G, Nogradi K, Galambos J, Vago I, Keseru GM, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012;22(10):3437–40.

    Article  CAS  PubMed  Google Scholar 

  10. Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–82.

    Article  PubMed  Google Scholar 

  12. Durgam S, Litman RE, Papadakis K, Li D, Nemeth G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61–8.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–7.

    Article  PubMed  Google Scholar 

  14. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–73.

    Article  CAS  PubMed  Google Scholar 

  15. Nemeth G, Laszlovszky I, Czobor P, Szalai E, Szatmari B, Harsanyi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–13.

    Article  CAS  PubMed  Google Scholar 

  16. Fleischhacker W, Galderisi S, Laszlovszky I, Szatmari B, Barabassy A, Acsai K, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9.

    Article  PubMed  Google Scholar 

  17. Nemeth B, Molnar A, Akehurst R, Horvath M, Koczian K, Nemeth G, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6(8):639–48.

    Article  PubMed  Google Scholar 

  18. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G, et al. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29(1):127–36.

    Article  CAS  PubMed  Google Scholar 

  19. Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res. 2019;204:282–8.

    Article  PubMed  Google Scholar 

  20. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–71.

    Article  PubMed  Google Scholar 

  21. Correll CU, Potkin SG, Zhong Y, Harsanyi J, Szatmari B, Earley W. Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. J Clin Psychiatry. 2019;80(2).

  22. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199–209.

    Article  CAS  PubMed  Google Scholar 

  23. Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39–50.

    Article  PubMed  Google Scholar 

  24. Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.

    Article  CAS  PubMed  Google Scholar 

  26. Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–92.

    Article  PubMed  Google Scholar 

  27. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.

    Article  CAS  PubMed  Google Scholar 

  28. Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol. 2015;25(11):1882–91.

    Article  CAS  PubMed  Google Scholar 

  29. McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord. 2019;257:600–6.

    Article  CAS  PubMed  Google Scholar 

  30. Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studies. J Affect Disord. 2017;215:205–12.

    Article  CAS  PubMed  Google Scholar 

  31. Earley W, Durgam S, Lu K, Ruth A, Nemeth G, Laszlovszky I, et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018;226:239–44.

    Article  PubMed  Google Scholar 

  32. Durgam S, Earley W, Lu K, Nemeth G, Laszlovszky I, Volk S, et al. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis. Int J Clin Pract. 2017;71(12).

  33. Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study. J Affect Disord. 2018;225:350–6.

    Article  CAS  PubMed  Google Scholar 

  34. Eaves S, Rey JA. Brexpiprazole (Rexulti): A New Monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. P T. 2016;41(7):418–22.

    PubMed  PubMed Central  Google Scholar 

  35. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.

    Article  PubMed  Google Scholar 

  36. Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology. 2020;45(5):786–92.

    Article  CAS  PubMed  Google Scholar 

  37. Citrome L, Stensbol TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15(10):1219–29.

    Article  CAS  PubMed  Google Scholar 

  38. Ward K, Citrome L. Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat. 2019;15:247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.

    Article  PubMed  Google Scholar 

  40. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–80.

    Article  PubMed  Google Scholar 

  41. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017;29(5):278–90.

    Article  PubMed  Google Scholar 

  42. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700.

    Article  CAS  PubMed  Google Scholar 

  43. Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445–53.

    Article  CAS  PubMed  Google Scholar 

  44. Marder SR, Eriksson H, Zhao Y, Hobart M. Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatr. 2020:1–6.

  45. Meade N, Shi L, Meehan SR, Weiss C, Ismail Z. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: post-hoc analysis of short- and long-term studies. J Psychopharmacol. 2020;34(8):829–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ishigooka J, Usami T, Iwashita S, Kojima Y, Matsuo S. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication). Neuropsychopharmacol Rep. 2020;40(2):122–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Malla A, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study. Int Clin Psychopharmacol. 2016;31(6):307–14.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Watson P, Zhang JP, Rizvi A, Tamaiev J, Birnbaum ML, Kane J. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr Res. 2018;202:26–36.

    Article  PubMed  Google Scholar 

  49. Ichinose M, Miura I, Horikoshi S, Yamamoto S, Kanno-Nozaki K, Watanabe K, et al. Effect of switching to brexpiprazole on plasma homovanillic acid levels and antipsychotic-related side effects in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr Dis Treat. 2021;17:1047–53.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Correll CU, Shi L, Weiss C, Hobart M, Eramo A, Duffy RA, et al. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019;24(5):507–17.

    Article  PubMed  Google Scholar 

  51. Citrome L, Ouyang J, Shi L, Meehan SR, Baker RA, Weiss C. Effect of brexpiprazole on agitation and hostility in patients with schizophrenia: post hoc analysis of short- and long-term studies. J Clin Psychopharmacol. 2019;39(6):597–603.

    Article  CAS  PubMed  Google Scholar 

  52. van Erp TG, Baker RA, Cox K, Okame T, Kojima Y, Eramo A, et al. Effect of brexpiprazole on control of impulsivity in schizophrenia: a randomized functional magnetic resonance imaging study. Psychiatry Res Neuroimaging. 2020;301:111085.

  53. Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21.

    CAS  PubMed  Google Scholar 

  54. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Vieta E, Sachs G, Chang D, Hellsten J, Brewer C, Peters-Strickland T, et al. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. J Psychopharmacol. 2021:269881120985102.

  56. El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol. 2010;20(11):776–83.

    Article  PubMed  Google Scholar 

  57. Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol. 2016;31(4):192–201.

    Article  PubMed  Google Scholar 

  59. Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018;34(12):2197–205.

    Article  CAS  PubMed  Google Scholar 

  60. Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. J Comp Eff Res. 2018;7(8):737–48.

    Article  PubMed  Google Scholar 

  61. Ivkovic J, Lindsten A, George V, Eriksson H, Hobart M. Effect of brexpiprazole on prolactin: an analysis of short- and long-term studies in schizophrenia. J Clin Psychopharmacol. 2019;39(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  62. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Blair HA. Lumateperone: first approval. Drugs. 2020;80(4):417–23.

    Article  CAS  PubMed  Google Scholar 

  64. Vanover KE, Davis RE, Zhou Y, Ye W, Brasic JR, Gapasin L, et al. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology. 2019;44(3):598–605.

    Article  CAS  PubMed  Google Scholar 

  65. Snyder GL, Vanover KE, Zhu H, Miller DB, O’Callaghan JP, Tomesch J, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology. 2015;232(3):605–21.

    Article  CAS  PubMed  Google Scholar 

  66. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature. 1989;342(6252):926–9.

    Article  CAS  PubMed  Google Scholar 

  67. Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989;342(6252):923–6.

    Article  CAS  PubMed  Google Scholar 

  68. Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016;16(6):601–14.

    Article  CAS  PubMed  Google Scholar 

  69. Svensson T DS, Hendrick J, Zhang L, Wennogle L, O'Gorman C, Snyder G, Marcus M, Mates S, Vanover K, Davis R. Lumateperone uniquely enhances glutamatergic neurotransmission through activation of both NMDA and AMPA channels via a dopamine D1 receptor-dependent mechanism: implications for treatment of mood disorders. ACNP 56th Annual Meeting: Poster Session II, December 5, 2017. Neuropsychopharmacology. 2017;42(1):S294-S475.

  70. Lieberman JA, Davis RE, Correll CU, Goff DC, Kane JM, Tamminga CA, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952–61.

    Article  CAS  PubMed  Google Scholar 

  71. Correll CU, Davis RE, Weingart M, Saillard J, O’Gorman C, Kane JM, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2020;77(4):349–58.

    Article  Google Scholar 

  72. Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1889–95.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Vanover K, Dmitrienko A, Glass S, Kozauer S, Saillard J, Weingart M, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching study. Schizophr Bull. 2018;44(Suppl 1):S341-S.

  74. Kane J VK, Davis R, et al. editor Efficacy and safety of lumateperone 42 Mg in the treatment of schizophrenia: a pooled analysis of randomized clinical trials. ACNP 58(th) Annual Meeting: Poster Session IIINeuropsychopharmacology; 2019 DecPMC6957926.

  75. Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. Int Clin Psychopharmacol. 2021.

  76. Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res. 2021;228:198–205.

    Article  PubMed  Google Scholar 

  77. Kitten AK, Hallowell SA, Saklad SR, Evoy KE. Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis. Innov Clin Neurosci. 2018;15(1–2):16–22.

    PubMed  PubMed Central  Google Scholar 

  78. Muneta-Arrate I, Diez-Alarcia R, Horrillo I, Meana JJ. Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Galphai1- and neutral antagonism for Galphaq/11-proteins in human brain cortex. Eur Neuropsychopharmacol. 2020;36:83–9.

    Article  CAS  PubMed  Google Scholar 

  79. Berg KA, Clarke WP. Making sense of pharmacology: inverse agonism and functional selectivity. Int J Neuropsychopharmacol. 2018;21(10):962–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Markham A. Pimavanserin: first global approval. Drugs. 2016;76(10):1053–7.

    Article  CAS  PubMed  Google Scholar 

  81. Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, et al. The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. J Clin Pharmacol. 2007;47(7):915–9.

    Article  CAS  PubMed  Google Scholar 

  82. Vanover KE, Robbins-Weilert D, Wilbraham DG, Mant TG, van Kammen DP, Davis RE, et al. Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol. 2007;47(6):704–14.

    Article  CAS  PubMed  Google Scholar 

  83. Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, Farde L, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol. 2008;11(2):163–71.

    Article  CAS  PubMed  Google Scholar 

  84. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35(4):881–92.

    Article  CAS  PubMed  Google Scholar 

  85. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.

    Article  CAS  PubMed  Google Scholar 

  86. Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, et al. Pimavanserin for Parkinson’s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Movement disorders : official journal of the Movement Disorder Society. 2018;33(11):1769–76.

    Article  CAS  Google Scholar 

  87. Isaacson SH, Coate B, Norton J, Stankovic S. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis. J Parkinsons Dis. 2020;10(4):1389–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Isaacson SH, Ballard CG, Kreitzman DL, Coate B, Norton JC, Fernandez HH, et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism Relat Disord. 2021;87:25–31.

    Article  PubMed  Google Scholar 

  89. Ballard CG, Kreitzman DL, Isaacson S, Liu IY, Norton JC, Demos G, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2020;77:100–6.

    Article  PubMed  Google Scholar 

  90. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2–3):144–52.

    Article  PubMed  Google Scholar 

  91. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.

    Article  PubMed  Google Scholar 

  92. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.

    Article  CAS  PubMed  Google Scholar 

  93. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

  94. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–70.

    Article  CAS  PubMed  Google Scholar 

  95. Weintraub DMZ. Spotlight debate—should we worry that pimavanserin might increase mortality amongst patients with Parkinson’s disease psychosis? US Neurology. 2019;15:2–7.

    Google Scholar 

  96. Mathis MV, Muoio BM, Andreason P, Avila AM, Farchione T, Atrakchi A, et al. The US Food and Drug Administration’s Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry. 2017;78(6):e668–73.

    Article  PubMed  Google Scholar 

  97. Yunusa I, El Helou ML, Alsahali S. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis. Front Pharmacol. 2020;11:87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. The Lancet Neurology. 2018;17(3):213–22.

    Article  CAS  PubMed  Google Scholar 

  99. Ballard CG, Coate B, Abler V, Stankovic S, Foff E. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis. Int J Geriatr Psychiatry. 2020;35(11):1402–8.

    Article  PubMed  Google Scholar 

  100. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455–82.

    Article  CAS  PubMed  Google Scholar 

  101. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009;19(8):2289–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Marczak ED, Jinsmaa Y, Myers PH, Blankenship T, Wilson R, Balboni G, et al. Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol. 2009;616(1–3):115–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018;40(11):1845–54 e2.

  105. Sun L, McDonnell D, Liu J, von Moltke L. Bioequivalence of olanzapine given in combination with samidorphan as a bilayer tablet (ALKS 3831) compared with olanzapine-alone tablets: results from a randomized, crossover relative bioavailability study. Clin Pharmacol Drug Dev. 2019;8(4):459–66.

    Article  CAS  PubMed  Google Scholar 

  106. Sun L, McDonnell D, Liu J, von Moltke L. Effect of food on the pharmacokinetics of a combination of olanzapine and samidorphan. Clin Pharmacol Drug Dev. 2019;8(4):503–10.

    Article  CAS  PubMed  Google Scholar 

  107. Sun L, Yagoda S, Du Y, von Moltke L. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet. Drug Des Devel Ther. 2019;13:2941–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Sun L, Yagoda S, Xue H, Brown R, Nangia N, McDonnell D, et al. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT/QTc study. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109881.

  109. Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018;195:245–51.

    Article  PubMed  Google Scholar 

  110. Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457–67.

    Article  PubMed  Google Scholar 

  111. Potkin SG, Kunovac J, Silverman BL, Simmons A, Jiang Y, DiPetrillo L, et al. Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study. J Clin Psychiatry. 2020;81(2).

  112. Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168–78.

    Article  PubMed  Google Scholar 

  113. Kahn RS, Silverman BL, DiPetrillo L, Graham C, Jiang Y, Yin J, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45–53.

    Article  PubMed  Google Scholar 

  114. Yagoda S, Graham C, Simmons A, Arevalo C, Jiang Y, McDonnell D. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. CNS Spectr. 2020:1–10.

  115. Carrithers B, El-Mallakh RS. Transdermal asenapine in schizophrenia: a systematic review. Patient Prefer Adherence. 2020;14:1541–51.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Reyad AA, Mishriky R. Asenapine: pharmacological aspects and role in psychiatric disorders. Psychiatr Danub. 2019;31(2):157–61.

    Article  CAS  PubMed  Google Scholar 

  117. Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10(6):893–903.

    Article  CAS  PubMed  Google Scholar 

  118. Citrome L, Zeni CM, Correll CU. Patches: established and emerging transdermal treatments in psychiatry. J Clin Psychiatry. 2019;80(4).

  119. Suzuki K, Castelli M, Komaroff M, Starling B, Terahara T, Citrome L. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). J Clin Psychopharmacol. 2021;41(3):286–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Abruzzo A, Cerchiara T, Luppi B, Bigucci F. Transdermal delivery of antipsychotics: rationale and current status. CNS Drugs. 2019;33(9):849–65.

    Article  CAS  PubMed  Google Scholar 

  121. Noven Therapeutics L. Secuado (asenapine) [prescribing information] Miami, FL.2019 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212268s000lbl.pdf.

  122. Citrome L, Walling DP, Zeni CM, Starling BR, Terahara T, Kuriki M, et al. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study. J Clin Psychiatry. 2020;82(1).

  123. Indivior. FDA approves PERSERIS (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults. 2018 [updated July 27]. Available from: Available from: http://indivior.com/wpcontent/uploads/2018/07/PERSERIS-Press-Release-FINAL.pdf.

  124. Ling W, Shoptaw S, Goodman-Meza D. Depot buprenorphine injection in the management of opioid use disorder: from development to implementation. Subst Abuse Rehabil. 2019;10:69–78.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125–32.

    Article  PubMed  Google Scholar 

  126. D'Souza S, Faraj JA, Giovagnoli S, Deluca PP. Development of risperidone PLGA microspheres. J Drug Deliv. 2014;2014:620464.

  127. Svendsen O, Blom L. Intramuscular injections and muscle damage: effects of concentration, volume, injection speed and vehicle. Arch Toxicol Suppl. 1984;7:472–5.

    Article  CAS  PubMed  Google Scholar 

  128. Gomeni R, Heidbreder C, Fudala PJ, Nasser AF. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol. 2013;53(10):1010–9.

    Article  CAS  PubMed  Google Scholar 

  129. Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014;53(6):533–43.

    Article  CAS  PubMed  Google Scholar 

  130. Citrome L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERISTM) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses. 2018;12(3):130–41.

    Article  PubMed  Google Scholar 

  131. Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130–40.

    Article  CAS  PubMed  Google Scholar 

  132. Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol. 2017;83(7):1476–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Isitt JJ, Nadipelli VR, Kouassi A, Fava M, Heidbreder C. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016;174(1–3):126–31.

    Article  PubMed  Google Scholar 

  134. Andorn A, Graham J, Csernansky J, Newcomer JW, Shinde S, Muma G, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol. 2019;39(5):428–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Dhanda R, Varghese D, Nadipelli VR, Fava M, Joshi N, Solem CT, et al. Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Prefer Adherence. 2019;13:1037–50.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Raedler LA. Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia. Am Health Drug Benefits. 2016;9(Spec Feature):40–3.

  137. Travis MJ, Burns T, Dursun S, Fahy T, Frangou S, Gray R, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract. 2005;59(4):485–95.

    Article  CAS  PubMed  Google Scholar 

  138. El-Mallakh PL, El-Mallakh RS. Adherence and assured administration of medications in bipolar patients. Curr Drug Deliv. 2013;10(6):706–12.

    Article  CAS  PubMed  Google Scholar 

  139. Heres S. Long-acting injectable antipsychotics: an underutilized treatment option. J Clin Psychiatry. 2014;75(11):1263–5.

    Article  PubMed  Google Scholar 

  140. Sommi RW, Rege B, Wehr A, Faldu S, Du Y, Weiden PJ. Aripiprazole lauroxil dosing regimens: understanding dosage strengths and injection intervals. CNS Spectr. 2020:1–6.

  141. Ehret MJ, Davis E, Luttrell SE, Clark C. Aripiprazole lauroxil NanoCrystal® dispersion technology (Aristada Initio®). Clin Schizophr Relat Psychoses. 2018;12(2):92–6.

    Article  PubMed  Google Scholar 

  142. Cruz MP. Aripiprazole lauroxil (Aristada): an extended-release, long-acting injection for the treatment of schizophrenia. P T. 2016;41(9):556–9.

    PubMed  PubMed Central  Google Scholar 

  143. Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Jain R, Meyer J, Wehr A, Rege B, von Moltke L, Weiden PJ. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectr. 2020;25(3):323–30.

    Article  PubMed  Google Scholar 

  145. Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159(2–3):404–10.

    Article  PubMed  Google Scholar 

  146. Hard ML, Wehr A, von Moltke L, Du Y, Farwick S, Walling DP, et al. Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. Ther Adv Psychopharmacol. 2019;9:2045125319859964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Meltzer HY, Risinger R, Nasrallah HA, Du Y, Zummo J, Corey L, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76(8):1085–90.

    Article  PubMed  Google Scholar 

  148. Potkin SG, Risinger R, Du Y, Zummo J, Bose A, Silverman B, et al. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation. Schizophr Res. 2017;190:115–20.

    Article  PubMed  Google Scholar 

  149. Targum SD, Risinger R, Du Y, Pendergrass JC, Jamal HH, Silverman BL. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophr Res. 2017;179:64–9.

    Article  PubMed  Google Scholar 

  150. Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, et al. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. Int Clin Psychopharmacol. 2016;31(2):69–75.

    Article  PubMed  Google Scholar 

  151. Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control ALPINE study. J Clin Psychiatry. 2020;81(3).

  152. Nasrallah HA, Aquila R, Stanford AD, Jamal HH, Weiden PJ, Risinger R. Metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil. Psychopharmacol Bull. 2017;47(3):35–43.

    PubMed  PubMed Central  Google Scholar 

  153. Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase i study and a population pharmacokinetic model. CNS Drugs. 2017;31(7):617–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Risinger R, Hard M, Weiden PJ. A phase-1 study comparing pharmacokinetic and safety profiles of three different dose intervals of aripiprazole lauroxil. Psychopharmacol Bull. 2017;47(3):26–34.

    PubMed  PubMed Central  Google Scholar 

  155. Weiden PJ, Du Y, von Moltke L, Wehr A, Hard M, Marandi M, et al. Pharmacokinetics, safety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44-week phase i study. CNS Drugs. 2020;34(9):961–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag. 2013;9:235–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154(11):1525–9.

    Article  CAS  PubMed  Google Scholar 

  158. Ferreri F, Drapier D, Baloche E, Ouzid M, Zimmer L, Llorca PM. The in vitro actions of loxapine on dopaminergic and serotonergic receptors. time to consider atypical classification of this antipsychotic drug? Int J Neuropsychopharmacol. 2018;21(4):355–60.

  159. Deniker P, Loo H, Cottereau MJ. Parenteral loxapine in severely disturbed schizophrenic patients. J Clin Psychiatry. 1980;41(1):23–6.

    CAS  PubMed  Google Scholar 

  160. Feldman HS. Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders. J Clin Pharmacol. 1982;22(8–9):366–70.

    Article  CAS  PubMed  Google Scholar 

  161. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry. 1986;47(3):126–9.

    CAS  PubMed  Google Scholar 

  162. Citrome L. Inhaled loxapine for agitation. Current Psychiatry. 2013 Feb 1;12(2):31-6.

  163. Noymer PMD, Glazer M, et al. The Staccato system: inhaler design characteristics for rapid treatment of CNS disorders. Resp Drug Deliv. 2010;1:11–20.

    Google Scholar 

  164. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169–79.

    Article  CAS  PubMed  Google Scholar 

  165. Takahashi LH, Huie K, Spyker DA, Fishman RS, Cassella JV. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit. 2014;36(5):618–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Selim S, Riesenberg R, Cassella J, Kunta J, Hellriegel E, Smith MA, et al. Pharmacokinetics and safety of single-dose inhaled loxapine in children and adolescents. J Clin Pharmacol. 2017;57(10):1244–57.

    Article  CAS  PubMed  Google Scholar 

  167. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313–21.

    Article  CAS  PubMed  Google Scholar 

  168. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–8.

    Article  PubMed  Google Scholar 

  169. Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31–40.

    Article  CAS  PubMed  Google Scholar 

  170. San L, Estrada G, Oudovenko N, Montanes F, Dobrovolskaya N, Bukhanovskaya O, et al. PLACID study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;28(6):710–8.

    Article  CAS  PubMed  Google Scholar 

  171. Ruch TNS, Yeruva RR, Gao Y, Tegin G, Terrell C, El-Mallakh RS. Inhaled loxapine for acute agitation in a psychiatric emergency service. Annals of Clinical Psychiatry (In Press). 2021.

  172. Gil E, Garcia-Alonso F, Boldeanu A, Baleeiro Teixeira T. Loxapine inhaled home use study investigator's t. Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial. BMJ Open. 2018;8(10):e020242.

  173. Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014;54(6):665–74.

    Article  CAS  PubMed  Google Scholar 

  174. Cassella JV, Spyker DA, Yeung PP. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(11):963–71.

  175. Spyker DA, Cassella JV, Stoltz RR, Yeung PP. Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study. Pharmacol Res Perspect. 2015;3(6):e00194.

  176. Gross N, Greos LS, Meltzer EO, Spangenthal S, Fishman RS, Spyker DA, et al. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease–two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014;27(6):478–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.

    Article  CAS  PubMed  Google Scholar 

  178. Schwartz MD, Canales JJ, Zucchi R, Espinoza S, Sukhanov I, Gainetdinov RR. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018;22(6):513–26.

    Article  CAS  PubMed  Google Scholar 

  179. Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–506.

    Article  CAS  PubMed  Google Scholar 

  180. Barak S, Weiner I. The M(1)/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol. 2011;14(9):1233–46.

    Article  CAS  PubMed  Google Scholar 

  181. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42(3):249–59.

    Article  CAS  PubMed  Google Scholar 

  182. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–9.

    Article  PubMed  Google Scholar 

  183. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433–46.

    Article  CAS  PubMed  Google Scholar 

  184. Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol. 2018;58(1):74–80.

    Article  CAS  PubMed  Google Scholar 

  186. Ishigooka J, Inada K, Niidome K, Aoki K, Kojima Y, Iwashita S, et al. Safety of switching to brexpiprazole in Japanese patients with schizophrenia: a post-hoc analysis of a long-term open-label study. Hum Psychopharmacol. 2021.

  187. Inada K, Yamada S, Akiyoshi H, Kojima Y, Iwashita S, Ishigooka J. Long-term efficacy and safety of brexpiprazole in elderly japanese patients with schizophrenia: a subgroup analysis of an open-label study. Neuropsychiatr Dis Treat. 2020;16:2267–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Weiss C, Weiller E, Baker RA, Duffy RA, Gwin KK, Zhang P, et al. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. Int Clin Psychopharmacol. 2018;33(5):255–60.

    Article  PubMed  PubMed Central  Google Scholar 

  189. Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP. Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med. 2011;12(2):134–41.

    Article  PubMed  PubMed Central  Google Scholar 

  190. Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898.e1-7.

    Article  Google Scholar 

  191. Ballard C, Youakim JM, Coate B, Stankovic S. Pimavanserin in Alzheimer’s disease psychosis: efficacy in patients with more pronounced psychotic symptoms. The journal of prevention of Alzheimer’s disease. 2019;6(1):27–33.

    CAS  PubMed  Google Scholar 

  192. Dammerman R, Kim S, Adera M, Schwarz A. Pharmacokinetics and safety of risperidone subcutaneous implants in stable patients with schizophrenia. Clin Pharmacol Drug Dev. 2018;7(3):298–310.

    Article  CAS  PubMed  Google Scholar 

  193. Miller BJ, Claxton A, Du Y, Weiden PJ, Potkin SG. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: a 6-month, prospective, open-label study. Schizophr Res. 2019;208:44–8.

    Article  PubMed  Google Scholar 

  194. Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395–403.

    Article  PubMed  Google Scholar 

  195. McEvoy JP, Weiden PJ, Lysaker PH, Sun X, O’Sullivan AK. Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia. BMC Psychiatry. 2021;21(1):164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Lauriello J, Claxton A, Du Y, Weiden PJ. Beyond 52-week long-term safety: long-term outcomes of aripiprazole lauroxil for patients with schizophrenia continuing in an extension study. J Clin Psychiatry. 2020;81(5).

  197. Citrome L, Du Y, Weiden PJ. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatr Dis Treat. 2019;15:2639–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Correll CU, Stanford AD, Claxton A, Du Y, Weiden PJ. Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Res. 2019;274:176–81.

    Article  CAS  PubMed  Google Scholar 

  199. Weiden PJ, Du Y, Liu CC, Stanford AD. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period. CNS Spectr. 2019;24(4):419–25.

    Article  PubMed  Google Scholar 

  200. McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD, et al. Durability of therapeutic response with long-term aripiprazole lauroxil treatment following successful resolution of an acute episode of schizophrenia. J Clin Psychiatry. 2017;78(8):1103–9.

    Article  PubMed  Google Scholar 

  201. Citrome L, Risinger R, Cutler AJ, Du Y, Zummo J, Nasrallah HA, et al. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the positive and negative syndrome scale-supportive analyses from a phase 3 study. CNS Spectr. 2018;23(4):284–90.

    Article  PubMed  Google Scholar 

  202. Nasrallah HA, Newcomer JW, Risinger R, Du Y, Zummo J, Bose A, et al. Effect of aripiprazole lauroxil on metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016;77(11):1519–25.

    Article  PubMed  Google Scholar 

  203. Hard ML, Wehr AY, Du Y, Weiden PJ, Walling D, von Moltke L. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. J Clin Psychopharmacol. 2018;38(5):435–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, University of Louisville, Louisville, KY, USA

    Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good & Rif S. El-Mallakh

Authors
  1. Mehak Pahwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmad Sleem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar H. Elsayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megan Elizabeth Good
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rif S. El-Mallakh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PRISMA mandates that multiple individuals review the same material, and all coauthors served as alternate reviewers. Each author was responsible for the primary review of several agents. Additionally, Mehak Pahwa and Rif S. El Mallakh were instrumental in the overall organization, Ahmad Sleem and Omar H. Elsayed for the organization of the tables, and Mehak Pahwa and Megan Elizabeth Good for writing the final discussion. Dr. El Mallakh was responsible for all aspects of the review.

Corresponding authors

Correspondence to Mehak Pahwa or Rif S. El-Mallakh.

Ethics declarations

Conflict of Interest

Dr. El Mallakh is a speaker for Eisai, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Noven, Otsuka, Sunovion, and Teva. None of the other authors have any potential conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Schizophrenia and Other Psychotic Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pahwa, M., Sleem, A., Elsayed, O.H. et al. New Antipsychotic Medications in the Last Decade. Curr Psychiatry Rep 23, 87 (2021). https://doi.org/10.1007/s11920-021-01298-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11920-021-01298-w

Keywords

Search

Navigation